Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04220970|
Recruitment Status : Recruiting
First Posted : January 7, 2020
Last Update Posted : July 26, 2021
Anaplastic large cell lymphoma associated with breast implants (BIA-ALCL) is a rare disease seen only in women with a breast implant.
Because of the low incidence of this disease and the peculiar histological subtype, French authorities, in accordance with the recommendations of an expert group, recommended the implementation of a BIA-ALCL case registry, in connection with a national Multidisciplinary meeting (Réunion de Concertation Pluridisciplinaire nationale de recours- RCP).
This registry is opened in France and in Belgium
|Condition or disease||Intervention/treatment|
|Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL)||Other: BIA-ALCL|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||150 participants|
|Target Follow-Up Duration:||13 Years|
|Official Title:||Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry|
|Actual Study Start Date :||June 7, 2017|
|Estimated Primary Completion Date :||June 7, 2032|
|Estimated Study Completion Date :||June 7, 2032|
Observational : no intervention
- Overall response [ Time Frame: 13 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04220970
|Contact: Manon Croix||+33 (04) 72 66 93 firstname.lastname@example.org|